New York, August 28, 2026, 09:39 (EDT)
- Roivant stock declined 2.7% to $36.58 during early trading on the Nasdaq.
- The FDA has authorized LISRAYA, making it the first oral treatment available for adults with dermatomyositis.
- JPMorgan estimates peak yearly U.S. sales could exceed $2 billion.
Shares in Roivant Sciences Ltd. NASDAQ: ROIV lost 2.7% on Friday, despite receiving U.S. regulatory approval for LISRAYA. The decline wiped out roughly $720 million in implied equity value.
The focus now moves from regulatory uncertainty to commercial implementation. LISRAYA is currently accessible via U.S. specialty pharmacies, Roivant said in its approval statement.
Speed is crucial. In the past, patients turned to steroids and other immune-suppressing therapies, which had not been specifically approved for dermatomyositis.
The FDA has cleared the 30-milligram oral tablet for once-daily use following results from a Phase 3 study of 241 patients. Researchers assessed two dosage levels against a placebo throughout a 52-week period.
The mean Total Improvement Score for patients receiving the approved dose reached 46.5, while those given placebo recorded 31.2, showing a difference of 15.3 points.
Improvements were seen by week four and continued through week 52. Patients receiving treatment lowered steroid use more than those given placebo.
| Investor measure | Verified figure | Why it matters |
|---|---|---|
| ROIV price | $36.58, falls 2.7% | Partial approval impact reflected in price |
| Market value | $26.42 billion | Forms basis for valuation |
| Peak U.S. sales estimate | Above $2 billion | Equals roughly 7.6% of today’s market value |
| Trial improvement score | 46.5 compared to 31.2 | Highlights clinical distinction |
| June cash and securities | $3.9 billion | Resources available for launch and pipeline |
Analyst Brian Cheng at JPMorgan projects that yearly U.S. sales will surpass $2 billion by the early 2030s, Reuters reported. This outlook represents approximately 7.6% of Roivant’s present market capitalization.
The number of potential patients is limited. Reuters reports that dermatomyositis impacts under 5,000 individuals in the United States.
The pricing details have not been revealed. According to Roivant, qualifying patients could pay as little as zero dollars per month, though the actual revenue will depend on insurer coverage.
The company begins launch backed by strong liquidity, posting $3.9 billion in cash, restricted cash and marketable securities as of June 30 quarterly results.
Roivant posted a net loss of $290.6 million for the quarter. The company spent $202 million on research and development, with revenue totaling $1.4 million.
On Friday, the price of $36.58 stayed close to the 52-week peak of $37.95. The stock began the session at $37.01, following a close of $37.58 on Thursday.
Risks: Uptake of LISRAYA could be impacted if specialty-drug reimbursement slows. The drug also includes boxed warnings regarding serious infections, malignancy, major cardiovascular events, and thrombosis.
The approval clears the main clinical obstacle. The following key data will relate to prescriptions, payer coverage, and published pricing.
Related articles: Pharmaceuticals
